TITLE:
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria

CONDITION:
Erythropoietic Protoporphyria

INTERVENTION:
cysteine hydrochloride

SUMMARY:

      OBJECTIVES:

      I. Determine the long-term efficacy and safety of L-cysteine in the prevention
      photosensitivity in patients with erythropoietic protoporphyria.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE: This is a phase III study, lasting 3 years; 1996-1999. Patients are
      administered L-cysteine orally twice daily, 2 capsules with breakfast and 2 with lunch.

      Patients fill in questionnaires and diary sheets about their reaction to sunlight exposure,
      and have blood tested 3 times a year.

      Completion date provided represents the completion date of the grant per OOPD records
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Erythropoietic protoporphyria RBC protoporphyrin greater than 50 micrograms/100 dL

        --Prior/Concurrent Therapy--

        At least 3 months since prior betacarotene or L-cysteine

        No concurrent betacarotene

        --Patient Characteristics--

          -  Fertile female patients must use effective contraception for duration of trial and
             for 3 weeks thereafter

          -  Not pregnant or nursing
      
